Ferguson opens OTC specialty shop

Share this article:

Feguson, a CommonHealth professional shop, launched a new “OTC Center of Excellence” focused on OTC marketing and promotion.

The group, led by EVP, director of client services Brian Doherty, will focus specifically on prescription drugs that transition to OTC, although the agency will also work on traditional OTC brands.

According to Doherty, who has been at CommonHealth for over a decade, the decision to launch an OTC group is a reflection of an evolving healthcare system. “Physicians aren't going to be able to devote as much time to ‘minor' conditions,” said Doherty, adding that self-care is on the rise. As a result, brand managers have to not only consider their share of the pharmacy shelf, but also their share of healthcare more generally, he said.

Doherty said Ferguson will bring its professional marketing experience to bear on OTC products. Although OTCs are governed by less strenuous marketing regulations than prescription drugs, “there are more similarities than differences,” said Doherty. “They still have to go through [internal] med/legal review.”

The OTC group will handle promotions for two of its preexisting clients—Novartis' line of consumer OTC products and Johnson & Johnson's oral and upper respiratory OTCs. Doherty said Ferguson worked on two of the most successful Rx-to-OTC transitions in history—presumably Zyrtec and Prevacid for J&J and Novartis, respectively—though Doherty refused to confirm specific brands.

The top nine out of 10 OTC brands switched from Rx to OTC, and one-third of OTC products overall contain an ingredient that was available by prescription-only at one time, said Doherty. “Work begins two or three years prior to patent expiration, and we continue to be in the brand creation business.” OTC products get a new label, and that's really where a brand begins, said Doherty.

Share this article:

Next Article in Features

Email Newsletters

More in Features

Leadership Exchange: How Do We Get Beyond the Pill?

Leadership Exchange: How Do We Get Beyond the ...

As its focus moves from manufacturing to service, pharma needs to partner with healthcare neophytes as well as established players. James Chase asks six experts to assess the risks and ...

FDA and off-label uses: a balancing act

FDA and off-label uses: a balancing act

FDA's current re-examination of its off-label promotion policies in light of the First Amendment is a delicate balancing act between its rock-solid traditional enforcement posture and a diverse new electronic ...

Read the complete August 2014 Digital Edition

Read the complete August 2014 Digital Edition

Click the above link to access the complete Digital Edition of the August 2014 issue of MM&M, with all text, charts and pictures.